| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498432 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US10592168 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US9827241 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US9272044 | INDIVIOR | Injectable flowable composition buprenorphine |
Jun, 2031
(7 years from now) | |
| US9782402 | INDIVIOR | Injectable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US10198218 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US10558394 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
| US8975270 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(7 years from now) | |
| US8921387 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(7 years from now) | |
| US11839611 | INDIVIOR | Buprenorphine dosing regimens |
Nov, 2035
(11 years from now) | |
| US11000520 | INDIVIOR | Buprenorphine dosing regimens |
Nov, 2035
(11 years from now) | |
| US10646484 | INDIVIOR | Methods to treat opioid use disorder |
Jun, 2038
(14 years from now) | |
Sublocade is owned by Indivior.
Sublocade contains Buprenorphine.
Sublocade has a total of 12 drug patents out of which 0 drug patents have expired.
Sublocade was authorised for market use on 30 November, 2017.
Sublocade is available in solution, extended release;subcutaneous dosage forms.
Sublocade can be used as treating opioid addiction by 100 mg or 300 mg dose buprenorphine, treating opioid addiction by subcutaneous injection of buprenorphine, treating opioid dependency by administering buprenorphine once monthly, treating opioid addiction by administering buprenorphine, in situ formation of solid buprenorphine composition, treating opioid dependency by administering buprenorphine once per month, treating opioid use disorder, treatment of moderate to severe opioid use disorder.
The generics of Sublocade are possible to be released after 22 June, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: In situ formation of solid buprenorphine composition; Treatment of moderate to severe opioid use disorder; Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; Treating opioid addiction b...
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
SUBLOCADE family patents
